×
About 7,790 results

ALLMedicine™ Angina Pectoris Center

Research & Reviews  1,746 results

Clinical Outcome of Revascularization Deferral With Instantaneous Wave-Free Ratio and F...
https://doi.org/10.1161/JAHA.122.028423
Journal of the American Heart Association; Berntorp K, Rylance R et. al.

Feb 4th, 2023 - Background Although physiology-based assessment of coronary artery stenosis using instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) are established methods of guiding coronary revascularization, its clinical outcome in long-ter...

Clinical Characteristics, Treatment Patterns, and Effectiveness in Chinese Patients wit...
https://doi.org/10.1007/s12325-023-02425-0
Advances in Therapy; Zhao X, Tong Z et. al.

Feb 4th, 2023 - Angina pectoris (AP) is the initial and the most common manifestation of coronary artery disease (CAD). Therefore, management and control of AP can help prevent further complications associated with CAD. However, there is under-reporting of angina...

The Coronary Sinus Reducer Stent for the Treatment of Refractory Angina Pectoris: From ...
https://doi.org/10.1097/CRD.0000000000000516
Cardiology in Review; Paz Y, Grosman-Rimon L et. al.

Feb 3rd, 2023 - The Neovasc Coronary Sinus Reducer Stent (CSRS) was developed for the treatment of patients who continue to suffer from disabling symptoms despite optimal medical therapy. This patient population with refractory angina symptoms is expected to grow...

Ruling Out Coronary Artery Disease and Myocardial Injury by Biomarkers
https://clinicaltrials.gov/ct2/show/NCT04144725

Feb 1st, 2023 - This is an observational study of patients with suspected coronary artery disease referred to coronary computed tomography angiography (CCTA). The plan is to include 1000 patients prior to CCTA at two centers. Blood samples for biomarker measureme...

Coronary artery disease in a patient with Addison's disease: a case report and literatu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884407
BMC Cardiovascular Disorders; Zhao R, Luo S et. al.

Jan 29th, 2023 - Addison's disease which is due to dysfunction of the adrenal gland, with abnormal secretion of glucocorticoids and mineralocorticoids, is rare. By inducing inflammation and disorders of water and electrolyte metabolism, Addison's disease may accel...

see more →

Guidelines  3 results

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

Recommendations for advancing the care of Canadians living with refractory angina pecto...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723022
The Canadian Journal of Cardiology; McGillion M, L'Allier PL et. al.

Jul 9th, 2009 - Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.|2009|McGillion M,L'Allier PL,Arthur H,Watt-Watson J,Svorkdal N,|epidemiology,therapy,epidemiology,

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

see more →

Drugs  940 results see all →

Clinicaltrials.gov  296 results

Ruling Out Coronary Artery Disease and Myocardial Injury by Biomarkers
https://clinicaltrials.gov/ct2/show/NCT04144725

Feb 1st, 2023 - This is an observational study of patients with suspected coronary artery disease referred to coronary computed tomography angiography (CCTA). The plan is to include 1000 patients prior to CCTA at two centers. Blood samples for biomarker measureme...

Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve
https://clinicaltrials.gov/ct2/show/NCT05682118

Jan 19th, 2023 - In coronary angiography, 50% or more stenosis of the causative vessel is observed in a patient with stable angina pectoris (SAP) or 50% or more stenosis of a non-causative vessel is observed in acute coronary syndrome (ACS) Based on 0.90, if it is...

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)
https://clinicaltrials.gov/ct2/show/NCT05623995

Jan 18th, 2023 - Chronic total occlusions (CTOs) are found in 15-25% of patients with stable angina pectoris. The presence of a CTO indicates unfavorable prognosis, with higher rate of major adverse cardiovascular events. Statins are frequently used after PCI in o...

The Effect of Progressive Relaxation Exercises on Sleep Quality
https://clinicaltrials.gov/ct2/show/NCT05647148

Dec 12th, 2022 - The data of this study will be collected between May 2022 and December 2022. The research will be carried out with a total of 60 (experimental group=30, control group=30) patients treated for heart failure, myocardial infarction and angina pectori...

Treatment of Coronary In-Stent Restenosis
https://clinicaltrials.gov/ct2/show/NCT01735825

Dec 8th, 2022 - In-stent restenosis after coronary angioplasty is currently one of the main limitations of this method, leading to a recurrence of exertional angina pectoris or manifesting as acute coronary syndrome. Histopathologic substrate of in-stent restenos...

see more →

News  123 results

Milk Bad, Cheese Not? Dairy Products Tied to Different CVD Risks
https://www.medscape.com/viewarticle/982935

Oct 24th, 2022 - Results from an observational study exploring the link between dairy intake and risk of cardiovascular disease events in patients with stable angina pectoris suggest different dairy products may have different health effects. The study, which anal...

Amcenestrant Provides Numerically Similar PFS to Endocrine Therapy in Endocrine-Resistant ER+ Advanced Breast Cancer
https://www.onclive.com/view/amcenestrant-provides-numerically-similar-pfs-to-endocrine-therapy-in-endocrine-resistant-er-advanced-breast-cancer

Sep 10th, 2022 - Amcenestrant (SAR439859) did not significantly improve progression-free survival (PFS) over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor (ER)–positive, HER2-negative advanced breast cancer, bu...

EU Approves Asciminib for Ph+ CML in Chronic Phase After 2 or More TKIs
https://www.onclive.com/view/eu-approves-asciminib-for-ph-cml-in-chronic-phase-after-2-or-more-tkis

Aug 29th, 2022 - The European Commission (EC) has approved asciminib (Scemblix) for the treatment of patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) in chronic phase who received prior treatment with at least 2 TKIs.1 The appr...

Orteronel Plus ADT Misses OS End Point in Metastatic Hormone-Sensitive Prostate Cancer
https://www.onclive.com/view/orteronel-plus-adt-misses-os-end-point-in-metastatic-hormone-sensitive-prostate-cancer

May 20th, 2022 - The addition of orteronel (TAK-700) to androgen deprivation therapy (ADT) vs bicalutamide improved progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic hormone-sensitive prostate cancer (mHSPC), ...

Real-world data suggest coprescribing PDE5 inhibitors and nitrates may be safe
https://www.mdedge.com/internalmedicine/article/253888/mens-health/real-world-data-suggest-coprescribing-pde5-inhibitors
Will Pass

Apr 19th, 2022 - As coprescribing drugs for erectile dysfunction and oral organic nitrates for ischemic heart disease (IHD) surged, cardiovascular adverse events did not significantly increase, a new study finds. The authors of the new research specifically examin.

see more →

Patient Education  8 results see all →